Dear Doctor Letter (Rote-Hand-Brief) on Cardioxane® (dexrazoxane): Restricted indications
2011.07.18
Active substance: dexrazoxane
Important safety information on restricted indications of Cardioxane® (dexrazoxane).
Notice (added on 24.02.2023)
In 2017, the European Medicines Agency (EMA) concluded an arbitration for Cardioxane (dexrazoxane, powder for solution for injection). As a result of the procedure, the contraindication for children and adolescents treated with high cumulative doses of anticancer drugs known as anthracyclines was lifted. However, for children and adolescents receiving lower cumulative doses of anthracyclines (total cumulative dose of less than 300 mg doxorubicin per m2 of body surface area or an equivalent dose of another anthracycline), the contraindication remains. For more information, please see the following link:
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN